How to Get Rezdiffra (Resmetirom) in South Dakota

What Is Rezdiffra and Why Does It Matter for South Dakota Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), previously called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, which enrolled 966 participants with biopsy-confirmed MASH and fibrosis stages F1B through F3.

That trial showed measurable results. At 52 weeks, 25.9% of patients receiving the 80 mg dose achieved MASH resolution without worsening fibrosis, compared with 9.7% on placebo. The 100 mg dose performed slightly better: 29.9% achieved MASH resolution versus the same placebo rate [1]. These are histological endpoints confirmed by liver biopsy, not surrogate markers.

South Dakota presents specific access challenges. The state has approximately 884,000 residents spread across 77,116 square miles, and hepatology specialists concentrate in Sioux Falls and Rapid City. Rural patients in communities like Pierre, Huron, or Winner may live three or more hours from the nearest gastroenterologist. This geography makes telehealth access particularly relevant for resmetirom prescribing.

The drug works as a thyroid hormone receptor beta (THR-beta) agonist, selectively activating liver-specific pathways that reduce hepatic fat accumulation and fibrosis progression. Unlike systemic thyroid hormone, resmetirom does not significantly affect heart rate, bone density, or the hypothalamic-pituitary-thyroid axis at approved doses [2]. That selectivity is what allowed Madrigal Pharmaceuticals to advance it through a liver-specific development program.

Who Can Prescribe Rezdiffra in South Dakota?

Any licensed prescriber holding an active South Dakota credential with prescriptive authority can write a Rezdiffra prescription. This includes physicians (MD and DO), nurse practitioners (NPs), and physician assistants (PAs).

South Dakota Board of Medical and Osteopathic Examiners rules do not restrict resmetirom to a specific specialty. A family medicine physician who confirms the diagnosis can legally prescribe it. In practice, most initial prescriptions originate from gastroenterologists or hepatologists because the diagnostic workup (imaging plus possible biopsy) typically occurs within those specialties.

NPs in South Dakota gained full practice authority under SDCL 36-9A, meaning they can prescribe without a collaborative agreement once they complete the required supervised practice period. PAs prescribe under their supervising physician's license per SDCL 36-4A. Both provider types can prescribe resmetirom and complete prior authorization paperwork.

For patients in rural areas without local GI specialists, primary care providers can initiate the diagnostic workup. A reasonable approach: the PCP orders a FibroScan or FIB-4 index, refers to a telehealth hepatologist for diagnostic confirmation and initial prescribing, and then manages ongoing monitoring locally. This hub-and-spoke model already operates for hepatitis C treatment across South Dakota's Indian Health Service facilities and can extend to MASH care.

Telehealth Pathways for Rezdiffra in South Dakota

South Dakota law permits telehealth prescribing of resmetirom. The state's telemedicine statute (SDCL 36-4-41.1) does not prohibit prescribing non-controlled substances through audio-video encounters, and resmetirom is not a scheduled drug.

Three telehealth models currently serve South Dakota patients seeking Rezdiffra access:

Health system virtual visits. Avera Health and Sanford Health, the two largest systems in South Dakota, both offer telehealth hepatology consultations. Patients anywhere in the state can schedule a video visit with a hepatologist based in Sioux Falls. These visits bill standard E/M codes and are typically covered by commercial insurance.

National telehealth platforms. Several hepatology-focused telehealth companies hold South Dakota licenses and can prescribe resmetirom to state residents. These platforms often bundle the diagnostic workup coordination, including ordering a FibroScan at a local imaging center, with the prescribing visit.

HealthRX telehealth consultations. HealthRX connects South Dakota patients with board-certified physicians experienced in MASH management who can evaluate candidacy, order required labs, and prescribe Rezdiffra through a streamlined telehealth workflow.

The telehealth prescriber must verify the patient's South Dakota address and confirm that diagnostic criteria are met before writing the prescription. A first visit typically lasts 30 to 45 minutes and covers medical history review, lab interpretation, imaging review, and treatment planning.

Required Labs and Diagnostic Workup Before Prescribing

Rezdiffra's FDA label specifies the drug for patients with MASH and moderate-to-advanced hepatic fibrosis (consistent with stages F2-F3). Confirming this diagnosis requires a structured workup. No provider should prescribe based on elevated liver enzymes alone.

Baseline labs (required before first prescription):

• Comprehensive metabolic panel (CMP) including ALT, AST, albumin, total bilirubin, and platelets
• Thyroid function panel (TSH, free T4) to rule out uncontrolled thyroid disease
• Lipid panel (resmetirom lowers LDL cholesterol, so baseline levels guide monitoring)
• HbA1c and fasting glucose (most MASH patients have concurrent metabolic syndrome)
• Hepatitis B surface antigen and hepatitis C antibody (to exclude viral hepatitis)
• FIB-4 index calculation (age, AST, ALT, platelet count)

Imaging confirmation:

The FIB-4 score triages patients, but imaging or biopsy confirms fibrosis stage. A vibration-controlled transient elastography (FibroScan) result between 8.0 and 13.9 kPa generally corresponds to F2-F3 fibrosis. Magnetic resonance elastography (MRE) is more accurate but less available in South Dakota's rural facilities.

FibroScan devices are available at Avera McKennan Hospital (Sioux Falls), Sanford USD Medical Center (Sioux Falls), Monument Health (Rapid City), and select regional clinics. Patients in western South Dakota may need to travel to Rapid City for the scan.

Liver biopsy: Not universally required for prescribing but considered the gold standard for fibrosis staging. The MAESTRO-NASH trial used biopsy-confirmed endpoints [1]. Some insurers request biopsy confirmation for prior authorization, though this requirement varies by plan.

Monitoring schedule after initiation: The FDA label recommends checking liver function tests at baseline, then periodically during treatment. A practical monitoring cadence: labs at week 12, week 24, then every 6 months. Thyroid function should be rechecked at 12 weeks. Any ALT elevation exceeding 5 times the upper limit of normal warrants treatment discontinuation and hepatology referral.

Insurance Coverage and Prior Authorization in South Dakota

Coverage for Rezdiffra varies sharply by payer type in South Dakota. The list price runs approximately $47,400 per year, making insurance coverage a determining factor for most patients.

South Dakota Medicaid: Does not cover Rezdiffra as of May 2026. The South Dakota Department of Social Services has not added resmetirom to the preferred drug list. Medicaid patients may pursue an exception request, but approval rates for drugs not on the PDL remain low. The AASLD practice guidance on MASLD management may support exception requests by documenting the clinical necessity.

Commercial insurance: Most major commercial plans in South Dakota (Avera Health Plans, Sanford Health Plan, Wellmark Blue Cross Blue Shield, DakotaCare) have established prior authorization criteria for Rezdiffra. Common requirements include:

1. Documented diagnosis of MASH (ICD-10 code K75.81)
2. Imaging or biopsy confirming fibrosis stage F2 or F3
3. Evidence that lifestyle modifications were attempted for at least 6 months
4. Baseline liver function tests within 90 days of the request
5. Prescriber attestation that the patient does not have decompensated cirrhosis (Child-Pugh B or C)

The prior authorization turnaround in South Dakota typically ranges from 5 to 15 business days. Denials can be appealed. The most common denial reason is insufficient documentation of fibrosis staging. Including the actual FibroScan report (not just the numerical result) with the PA submission reduces denial rates.

Medicare Part D: Coverage decisions vary by plan. Some Medicare Advantage plans operating in South Dakota have added Rezdiffra to specialty tier formularies with step therapy requirements. Patients should verify with their specific plan.

Madrigal Pharmaceuticals patient assistance: Madrigal offers the Rezdiffra Patient Support Program for commercially insured patients, which can reduce copays to as little as $0 for eligible patients. Uninsured patients may qualify for free drug through the manufacturer's patient assistance program, subject to income verification.

503A Compounding Pharmacy Access in South Dakota

South Dakota permits 503A compounding pharmacies to prepare patient-specific prescriptions for resmetirom. This pathway exists but comes with important distinctions from the commercially manufactured Rezdiffra product.

A 503A pharmacy compounds medications based on individual prescriptions from a licensed prescriber. In South Dakota, the Board of Pharmacy regulates these facilities under SDCL 36-11. The pharmacy must hold an active South Dakota compounding license, and the prescription must specify the patient by name.

Key considerations for the 503A route:

Bioequivalence is not guaranteed. Compounded resmetirom has not undergone FDA bioequivalence testing against the commercial Rezdiffra tablet. The active ingredient may be identical, but excipients, dissolution rates, and manufacturing controls differ. Patients and prescribers should weigh this tradeoff, particularly since the MAESTRO-NASH efficacy data [1] were generated using the manufactured product.

Cost may be lower. Compounded resmetirom typically costs between $200 and $600 per month, depending on the pharmacy and dose. This represents a significant reduction from the $3,950 per month list price of branded Rezdiffra.

Shipping is permitted. 503A pharmacies based in South Dakota or holding South Dakota non-resident pharmacy licenses can ship compounded resmetirom directly to patients within the state. The prescription must specify the exact dose and formulation.

Insurance will not cover compounded versions. Commercial insurers and Medicare do not reimburse for compounded resmetirom. This is a cash-pay pathway.

Several 503A pharmacies with South Dakota licenses have added resmetirom to their formularies. Patients should confirm that the pharmacy sources pharmaceutical-grade resmetirom API from an FDA-registered supplier and provides a certificate of analysis with each fill.

The Prescription-to-Delivery Timeline

South Dakota patients should expect the following timeline from initial consultation to receiving their first dose of Rezdiffra. The process rarely happens in under two weeks, and four to six weeks is common.

Week 1: Initial consultation (in-person or telehealth). Provider reviews history, orders baseline labs and FibroScan if not already completed.

Weeks 1-2: Labs drawn and imaging completed. FibroScan availability may add a few days in rural areas. Results returned to prescriber.

Week 2-3: Prescriber confirms MASH with F2-F3 fibrosis, selects the appropriate dose (80 mg for patients weighing <100 kg, 100 mg for patients weighing 100 kg or more per the FDA label), and submits the prescription with prior authorization to the patient's insurer.

Weeks 3-5: Prior authorization review. If approved, the insurer authorizes the specialty pharmacy to fill the prescription. If denied, the prescriber submits an appeal with additional documentation.

Week 4-6: Specialty pharmacy ships Rezdiffra to the patient's home or designated pickup location. Most specialty pharmacies offer free overnight shipping to South Dakota addresses.

For the 503A compounding route, the timeline compresses significantly. Once the prescriber writes the prescription, most compounding pharmacies can fill and ship within 3 to 7 business days. No prior authorization is required.

Weight-Based Dosing and Ongoing Management

Rezdiffra dosing is weight-based. Patients weighing less than 100 kg take 80 mg once daily. Patients at 100 kg or above take 100 mg once daily. Both doses are taken orally with or without food [2].

The MAESTRO-NASH trial demonstrated that the most common adverse events were diarrhea (27.2% vs. 18.5% placebo) and nausea (15.1% vs. 13.3% placebo) [1]. Most GI side effects were mild and resolved within the first four weeks of treatment.

Lipid effects deserve attention. Resmetirom reduced LDL cholesterol by approximately 14% at the 80 mg dose and 22% at the 100 mg dose in the MAESTRO-NASH trial [1]. Patients already on high-intensity statins should have their lipid panel monitored at 12 weeks, as LDL levels may drop below the point where statin dose reduction is reasonable.

According to the Endocrine Society's 2023 clinical practice guideline on NAFLD/MASH management, thyroid hormone receptor agonists represent a targeted approach to hepatic steatosis that does not require the caloric restriction seen with GLP-1 receptor agonists. This distinction matters for South Dakota patients who may already be prescribed semaglutide or tirzepatide for weight management. Resmetirom can be used alongside GLP-1 receptor agonists, as the MAESTRO-NASH trial did not exclude patients on these agents.

Long-term management includes repeat FibroScan at 12 months to assess treatment response. A decrease of 2 or more kPa suggests meaningful fibrosis improvement. The ongoing MAESTRO-OUTCOMES trial (NCT03900429) is evaluating whether resmetirom reduces liver-related clinical events (decompensation, transplant, death) over 54 months, with results expected by 2028 [3].

Transferring a Rezdiffra Prescription to South Dakota

Patients relocating to South Dakota from another state can transfer an existing Rezdiffra prescription. South Dakota Board of Pharmacy rules permit prescription transfers from any U.S. state for non-controlled substances.

The process requires the receiving South Dakota pharmacy (or specialty pharmacy licensed in South Dakota) to contact the originating pharmacy and complete the transfer per SDCL 36-11-46. Specialty pharmacy transfers sometimes take longer because the new pharmacy must re-verify insurance benefits and potentially submit a new prior authorization under the patient's updated address.

Patients should request their complete medical records, including the FibroScan report and original prescriber's documentation of MASH with F2-F3 fibrosis, before moving. This documentation prevents the need to repeat the entire diagnostic workup in South Dakota.

A gap in therapy of more than 30 days does not require dose re-titration. Patients can resume at their previous dose. Any gap exceeding 90 days should prompt repeat liver function tests before restarting.